CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank
CytoMed Therapeutics (NASDAQ: GDTC) has acquired a cord blood banking licence and assets through its subsidiary, IPSC Depository Sdn Bhd. The acquisition includes a licence from Malaysia's Ministry of Health, cryopreservation equipment with over 12,000 cord blood units, and two freehold properties. This move expands CytoMed's strategy in cell therapies, providing access to rare cord blood for research and development in regenerative medicine and aging diseases.
The new biotechnology arm will be operated through CytoMed's subsidiary, LongevityBank Pte . Evelyn Tan, CEO of IPSC Depository Sdn Bhd, stated that this acquisition aims to unlock the therapeutic potential of umbilical cord blood, targeting longevity and wellness. CytoMed's co-CEO, Dr Tan Wee Kiat, highlighted the synergy between CytoMed and IPSC Depository in deriving immune gamma delta T cells from cord blood to fight cancers.
CytoMed Therapeutics (NASDAQ: GDTC) ha acquisito una licenza per la conservazione del sangue cordonale e beni attraverso la sua controllata, IPSC Depository Sdn Bhd. L'acquisizione include una licenza del Ministero della Salute della Malaysia, attrezzature di crioconservazione con oltre 12.000 unità di sangue cordonale, e due proprietà a pieno titolo. Questa mossa amplia la strategia di CytoMed nelle terapie cellulari, fornendo accesso a sangue cordonale raro per la ricerca e lo sviluppo nella medicina rigenerativa e nelle malattie legate all'invecchiamento.
Il nuovo settore biotecnologico sarà gestito attraverso la controllata di CytoMed, LongevityBank Pte. Evelyn Tan, CEO di IPSC Depository Sdn Bhd, ha dichiarato che questa acquisizione mira a sbloccare il potenziale terapeutico del sangue cordonale, con un focus sulla longevità e il benessere. Il co-CEO di CytoMed, Dr Tan Wee Kiat, ha sottolineato la sinergia tra CytoMed e IPSC Depository nel derivare cellule T gamma delta immunitarie dal sangue cordonale per combattere i tumori.
CytoMed Therapeutics (NASDAQ: GDTC) ha adquirido una licencia de almacenamiento de sangre del cordón umbilical y activos a través de su filial, IPSC Depository Sdn Bhd. La adquisición incluye una licencia del Ministerio de Salud de Malasia, equipos de crioconservación con más de 12,000 unidades de sangre del cordón, y dos propiedades de pleno derecho. Este movimiento amplía la estrategia de CytoMed en terapias celulares, proporcionando acceso a sangre del cordón rara para la investigación y el desarrollo en medicina regenerativa y enfermedades relacionadas con el envejecimiento.
La nueva división biotecnológica será operada a través de la filial de CytoMed, LongevityBank Pte. Evelyn Tan, CEO de IPSC Depository Sdn Bhd, declaró que esta adquisición tiene como objetivo desbloquear el potencial terapéutico de la sangre del cordón umbilical, enfocándose en la longevidad y el bienestar. El co-CEO de CytoMed, Dr Tan Wee Kiat, destacó la sinergia entre CytoMed e IPSC Depository en la obtención de células T gamma delta del cordón umbilical para combatir el cáncer.
CytoMed Therapeutics (NASDAQ: GDTC)는 자회사인 IPSC Depository Sdn Bhd를 통해 제대혈 은행 라이센스와 자산을 인수했습니다. 이번 인수에는 말레이시아 보건부의 라이센스, 12,000개 이상의 제대혈 샘플을 위한 냉동 보존 장비, 두 개의 소유 부동산이 포함됩니다. 이 조치는 세포 치료에서 CytoMed의 전략을 확장하며, 재생 의학 및 노화 관련 질환 연구와 개발을 위한 희귀 제대혈 접근을 제공합니다.
새로운 생명공학 부문은 CytoMed의 자회사인 LongevityBank Pte를 통해 운영될 것입니다. IPSC Depository Sdn Bhd의 CEO인 Evelyn Tan은 이번 인수가 제대혈의 치료 잠재력을 개방하여 장수 및 웰빙을 목표로 한다고 밝혔습니다. CytoMed의 공동 CEO인 Dr Tan Wee Kiat는 제대혈에서 면역 감마 델타 T 세포를 유도하여 암을 치료하는 CytoMed와 IPSC Depository 간의 시너지를 강조했습니다.
CytoMed Therapeutics (NASDAQ: GDTC) a acquis une licence de banking de sang de cordon et des actifs par le biais de sa filiale, IPSC Depository Sdn Bhd. L'acquisition comprend une licence du ministère de la Santé de Malaisie, des équipements de cryoconservation avec plus de 12,000 unités de sang de cordon, et deux propriétés en pleine propriété. Ce déménagement élargit la stratégie de CytoMed dans les thérapies cellulaires, permettant l'accès à du sang de cordon rare pour la recherche et le développement en médecine régénérative et les maladies liées au vieillissement.
Le nouveau bras biotechnologique sera opéré par la filiale de CytoMed, LongevityBank Pte. Evelyn Tan, PDG d'IPSC Depository Sdn Bhd, a déclaré que cette acquisition vise à libérer le potentiel thérapeutique du sang de cordon ombilical, ciblant la longévité et le bien-être. Le co-PDG de CytoMed, Dr Tan Wee Kiat, a souligné la synergie entre CytoMed et IPSC Depository dans la dérivation des cellules T gamma delta immunitaires à partir du sang de cordon pour lutter contre le cancer.
CytoMed Therapeutics (NASDAQ: GDTC) hat eine Lizenz und Vermögenswerte für eine Nabelschnurblutbank über ihre Tochtergesellschaft, IPSC Depository Sdn Bhd, erworben. Die Akquisition umfasst eine Lizenz des malaysischen Gesundheitsministeriums, Kryokonservierungsausrüstung mit über 12.000 Nabelschnurblutproben und zwei unbebautes Grundstücke. Dieser Schritt erweitert die Strategie von CytoMed in der Zelltherapie und bietet Zugang zu seltenem Nabelschnurblut für Forschung und Entwicklung in der regenerativen Medizin und bei Alterskrankheiten.
Der neue biotechnologische Bereich wird über die Tochtergesellschaft von CytoMed, LongevityBank Pte, betrieben. Evelyn Tan, CEO von IPSC Depository Sdn Bhd, erklärte, dass diese Akquisition darauf abzielt, das therapeutische Potenzial von Nabelschnurblut zu erschließen und auf Langlebigkeit und Wohlbefinden abzuzielen. Der Co-CEO von CytoMed, Dr. Tan Wee Kiat, betonte die Synergie zwischen CytoMed und IPSC Depository bei der Gewinnung von immunkompatiblen gamma-delta T-Zellen aus Nabelschnurblut zur Bekämpfung von Krebs.
- Acquisition of cord blood banking licence and assets expands CytoMed's cell therapy capabilities
- Access to over 12,000 cord blood units for research and development
- Potential for developing therapies in regenerative medicine and aging-related diseases
- Synergy between CytoMed and IPSC Depository for cancer-fighting cell therapies
- Ownership of state-of-the-art GMP laboratory for quality control and cost management
- Potential integration challenges and operational costs associated with the acquisition
- Increased complexity in business operations with the new subsidiary
- Possible dilution of focus from core cancer therapeutics business
Insights
This acquisition marks a significant strategic expansion for CytoMed Therapeutics. By acquiring a cord blood banking license and assets, including 12,000+ cord blood units and real estate, the company gains valuable resources for cell therapy research and development. The move into cord blood-derived biologics through LongevityBank broadens CytoMed's potential market beyond cancer therapeutics to include regenerative medicine and longevity applications.
Key points:
- Access to rare cord blood samples for R&D
- Expansion into regenerative medicine and anti-aging therapies
- Potential for future spin-off of LongevityBank subsidiary
- Synergies with existing cancer therapy research
While promising, investors should note that commercialization of cord blood therapies is still in early stages. The
This acquisition provides CytoMed with a significant competitive advantage in the cell therapy space. Cord blood contains valuable naïve stem cells and immune cells that have shown promise in treating autoimmune diseases, cancer and age-related conditions. The 12,000+ cord blood units represent a treasure trove of research material.
From a scientific perspective, key benefits include:
- Access to gamma delta T cells from cord blood for cancer therapies
- Potential to develop novel regenerative medicine applications
- Synergy with CytoMed's existing CAR-T cell manufacturing capabilities
The company's GMP lab and patented technologies position it well to translate research into clinical applications. However, the field is still evolving and successful commercialization will require overcoming significant regulatory and scientific hurdles. This move diversifies CytoMed's research pipeline but also increases complexity and resource requirements.
SINGAPORE, Oct. 03, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, has through its subsidiary, IPSC Depository Sdn Bhd, acquired the licence and certain assets of Cellsafe International Sdn Bhd (In Liquidation), a Malaysian cord blood bank.
The acquisition includes (i) a cord blood banking licence issued by Malaysia’s Ministry of Health, (ii) cryopreservation equipment with more than 12,000 cord blood units (“CBUs”) and (iii) two freehold real estate properties totalling 189 square metres in which the operation is situated.
This acquisition will expand CytoMed’s strategy in cell therapies as it now has access to rare and precious naïve cord blood donated for research and development. There are abundant clinical publications and evidence that cord blood offers a wide range of opportunities in the fields of regenerative medicine and aging diseases, including auto-immune diseases. This new biotechnology arm will be undertaken through CytoMed’s subsidiary, LongevityBank Pte Ltd. The latter is the holding company of IPSC Depository Sdn Bhd which holds the cord blood banking licence issued by the Ministry of Health, Malaysia.
Once considered medical waste, cord blood has emerged as a valuable raw material with significant therapeutic potential in cell therapies. However, cord blood is a rare and expensive resource unlike adult blood mononuclear cells, which are readily accessible and a common raw material for researchers. In recent years, researchers have made significant strides in harnessing the unique properties of cord blood derived cells for combating auto-immune diseases and cancer, as well as promoting healthy aging.
“This acquisition seeks to unlock the therapeutic potential of umbilical cord blood and adds a new strategic dimension targeting longevity and wellness,” said Evelyn Tan, the newly appointed CEO of IPSC Depository Sdn Bhd. She added “While CytoMed, our publicly listed holding company, will continue to focus on cancer therapeutics, LongevityBank Pte Ltd will focus exclusively on the regenerative medicine market, with its ultimate goal to be spun off in the future.”
CytoMed’s co-CEO Dr Tan Wee Kiat added “Mononuclear cells in the CBU are the starting raw material from which many cell therapies can be derived. In addition to longevity targets, there is clear synergy between CytoMed and IPSC Depository to focus on deriving immune gamma delta T cells from cord blood to fight cancers. We own our state-of-the-art, current Good Manufacturing Practice laboratory to ensure quality and cost-control, and have patented technologies to manufacture clinical grade chimeric antigen receptor cells, or CAR-T cells as adjunctive therapies, should the no-option patient’s doctor recommend it.”
The Company will be inviting experts in longevity field to join its board of directors or as advisers as it seeks to develop and grow this subsidiary as a specialised umbilical cord blood-derived cell therapy arm.
About CytoMed Therapeutics Limited (CytoMed)
Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency in the public sector. It is a biopharmaceutical company focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumours. For more information, please visit www.cytomed.sg and follow us on Twitter (“X”) @CytomedSG,on LinkedIn, and Facebook
Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company's current and future pre-clinical studies and clinical trials and the Company's R&D programs; the Company's expectations regarding the impact of future COVID-19 outbreak on its business, the Company's industry and the economy; the Company's estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company's ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company's ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.
Contact :
CytoMed Therapeutics Limited
enquiry@cytomed.sg
Attention :
Evelyn Tan
Chief Corporate Officer, CytoMed Therapeutics Limited;
Chief Executive Officer of IPSC Depository Sdn Bhd
FAQ
What did CytoMed Therapeutics (GDTC) acquire in its recent transaction?
How does the acquisition of cord blood assets benefit CytoMed Therapeutics (GDTC)?
What is the role of LongevityBank Pte in CytoMed Therapeutics' (GDTC) recent acquisition?
How does CytoMed Therapeutics (GDTC) plan to utilize the acquired cord blood units?
